NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease

American Journal of Medicine

Volumn 127, Issue 1, 2014, Pages

  Kohli, Payal ^a   Steg, Ph Gabriel ^b   Cannon, Christopher P ^c,d   Smith, Sidney C ^e   Eagle, Kim A ^f   Ohman, E Magnus ^g   Alberts, Mark J ^h   Hoffman, Elaine ^c   Guo, Jianping ^c   Simon, Tabassome ^i,l   Sorbets, Emmanuel ^b   Goto, Shinya ^j   Bhatt, Deepak L ^c,d,k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j TOKAI UNIVERSITY   (Japan)

^k VA BOSTON HEALTHCARE SYSTEM   (United States)

^l INSERM   (France)

more..

Author keywords

Heart failure; NSAID; Outcomes; Stable atherothrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; STABLE ATHEROTHROMBOTIC DISEASE; THROMBOSIS;

EID: 84891626164     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.08.017     Document Type: Article

References (36)

1. A. Helin-Salmivaara, A. Virtanen, and R. Vesalainen et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland Eur Heart J 27 14 2006 1657 1663
2. M.E. Farkouh, and B.P. Greenberg An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs Am J Cardiol 103 9 2009 1227 1237
3. P. McGettigan, P. Han, and D. Henry Cyclooxygenase-2 inhibitors and coronary occlusion - exploring dose-response relationships Br J Clin Pharmacol 62 3 2006 358 365
4. P. McGettigan, and D. Henry Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 13 2006 1633 1644
5. P. McGettigan, and D. Henry Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies PLoS Med 8 9 2011 e1001098
6. S. Trelle, S. Reichenbach, and S. Wandel et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
7. A.M. Schjerning Olsen, E.L. Fosbol, and J. Lindhardsen et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study Circulation 123 20 2011 2226 2235
8. C.P. Cannon, and P.J. Cannon Physiology. Cox-2 inhibitors and cardiovascular risk Science 336 6087 2012 1386 1387
9. Y. Yu, E. Ricciotti, and R. Scalia et al. Vascular Cox-2 modulates blood pressure and thrombosis in mice Sci Transl Med 4 132 2012 132ra54
10. V.J. Dzau, M. Packer, L.S. Lilly, S.L. Swartz, N.K. Hollenberg, and G.H. Williams Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia N Engl J Med 310 6 1984 347 352
11. J. Feenstra, E.R. Heerdink, D.E. Grobbee, and B.H. Stricker Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study Arch Intern Med 162 3 2002 265 270
12. T.J. Aw, S.J. Haas, D. Liew, and H. Krum Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Arch Intern Med 165 5 2005 490 496
13. G.H. Gislason, J.N. Rasmussen, and S.Z. Abildstrom et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure Arch Intern Med 169 2 2009 141 149
14. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 25 2001 1809 1817
15. P.J. Loll, D. Picot, and R.M. Garavito The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase Nat Struct Biol 2 8 1995 637 643
16. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K.A. Taubert Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association Circulation 115 12 2007 1634 1642
17. P. McGettigan, and D. Henry Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries PLoS Med 10 2 2013 e1001388
18. E.M. Ohman, D.L. Bhatt, and P.G. Steg et al. The REduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events - study design Am Heart J 151 4 2006 786.e1 786.e10
19. P.G. Steg, D.L. Bhatt, and P.W. Wilson et al. One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 11 2007 1197 1206
20. D.L. Bhatt, K.A. Eagle, and E.M. Ohman et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 304 12 2010 1350 1357
21. M.J. Alberts, D.L. Bhatt, and J.L. Mas et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry Eur Heart J 30 19 2009 2318 2326
22. K.A. Eagle, A.T. Hirsch, and R.M. Califf et al. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the United States: insights from the REACH Registry Crit Pathw Cardiol 8 2 2009 91 97
23. A.A. Bavry, A. Khaliq, and Y. Gong et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease Am J Med 124 7 2011 614 620
24. O. Barthélémy, T. Limbourg, and J.P. Collet et al. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors Int J Cardiol 163 3 2013 266 271
25. G. Singh, J.D. Miller, D.M. Huse, D. Pettitt, R.B. D'Agostino, and M.W. Russell Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis J Rheumatol 30 4 2003 714 719
26. E.L. Fosbol, F. Folke, and S. Jacobsen et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals Circ Cardiovasc Qual Outcomes 3 4 2010 395 405
27. M. Mamdani, D.N. Juurlink, and D.S. Lee et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet 363 9423 2004 1751 1756
28. A.M. Schjerning Olsen, E.L. Fosbol, and J. Lindhardsen et al. Long-term cardiovascular risk of NSAID use according to time passed after first-time myocardial infarction: a nationwide cohort study Circulation 126 16 2012 1955 1963
29. D.L. Bhatt NSAIDs and the risk of myocardial infarction: do they help or harm? Eur Heart J 27 14 2006 1635 1636
30. S. Bak, M. Andersen, and I. Tsiropoulos et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study Stroke 34 2 2003 379 386
31. F. Andersohn, R. Schade, S. Suissa, and E. Garbe Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study Stroke 37 7 2006 1725 1730
32. T.A. Lee, B. Bartle, and K.B. Weiss Impact of NSAIDs on mortality and the effect of preexisting coronary artery disease in US veterans Am J Med 120 1 2007 98.e9 98.e16
33. D.H. Solomon, J. Avorn, T. Sturmer, R.J. Glynn, H. Mogun, and S. Schneeweiss Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk Arthritis Rheum 54 5 2006 1378 1389
34. T. Hohlfeld, A. Saxena, and K. Schror High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance Thromb Haemost 109 5 2013 825 833
35. M.C. Becker, T.H. Wang, and L. Wisniewski et al. Rationale, design, and governance of prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (precision), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis Am Heart J 157 4 2009 606 612
36. Coxib and traditional NSAID Trialists' (CNT) Collaboration N. Bhala, J. Emberson, and A. Merhi et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials Lancet 382 9894 2013 769 779